NEW YORK – NeoGenomics said Monday that its recent efforts to optimize its operations and maximize revenue from a broad portfolio of molecular diagnostics and pathology services is paying off as it prepares to stake a claim in new markets like minimal residual disease (MRD) testing. In mid-March, the company…Read More
NeoGenomics Turnaround Takes Hold as Firm Begins Clinical Push for Radar MRD Test
